Sun Xian Wen, Ding Yong Jie, Zhang Yu Yan, Chen Pei Li, Yan Ya Ru, Shen Ji Min, Li Qing Yun
Department of Respiratory Medicine and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China.
Department of Respiratory Medicine, Zhongwei People's Hospital, Ningxia Hui Autonomous Region 751700, P.R. China.
Mol Clin Oncol. 2018 Aug;9(2):192-196. doi: 10.3892/mco.2018.1651. Epub 2018 Jun 11.
Invasive mucinous adenocarcinoma (IMA) was formerly referred to as mucinous bronchioloalveolar carcinoma. The lack of effective chemotherapy and comprehensive treatment for this type of tumor poses a great challenge in clinical practice. We herein report the case of a male patient with IMA who was treated with a combination of pemetrexed (500 mg/m), cisplatin (75 mg/m) and bevacizumab (15 mg/kg) as first-line chemotherapy. The patient achieved significant radiological improvement with 6 courses of this regimen. After the tumor progressed, the patient again achieved marked improvement with an additional 4 courses of the same regimen. The patient survived for a total of 30 months after the first chemotherapy. Therefore, bevacizumab in combination with pemetrexed/cisplatin may be an effective strategy for the treatment of IMA. The available literature on this chemotherapy regimen was also reviewed and discussed in the present study.
浸润性黏液腺癌（IMA）曾被称为黏液性细支气管肺泡癌。这类肿瘤缺乏有效的化疗及综合治疗方案，给临床实践带来了巨大挑战。我们在此报告1例IMA男性患者，接受培美曲塞（500 mg/m²）、顺铂（75 mg/m²）和贝伐单抗（15 mg/kg）联合方案作为一线化疗。该患者接受6个疗程此方案治疗后影像学表现显著改善。肿瘤进展后，患者再次接受相同方案4个疗程治疗，又取得明显改善。首次化疗后患者共存活30个月。因此，贝伐单抗联合培美曲塞/顺铂可能是治疗IMA的有效策略。本研究还对关于该化疗方案的现有文献进行了回顾和讨论。
